Orchard Therapeutics PLC $ 11.53 0 (0%)
Volume:
77,510
Avg Vol (1m):
196,560
Market Cap $:
990.08 Mil
Enterprise Value $:
654.24 Mil
P/E (TTM):
1.95
P/B:
2.63
| Net Current Asset Value | ||
| Tangible Book | ||
| Median P/S Value | ||
| Graham Number | ||
|
Price: $11.53 | ||
Manual of Stocks™ Web
Financial Strength | 8.2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 17.12 | ||
| Equity-to-Asset | 0.85 | ||
| Debt-to-EBITDA | -0.17 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 14.52 | ||
Profitability | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -11321.34 | ||
| Net Margin % | -11102.84 | ||
| ROE % | -60.33 | ||
| ROA % | -47.33 | ||
| ROC (Joel Greenblatt) % | -2649.08 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 1.95 | ||
| PE Ratio without NRI | 1.95 | ||
| PB Ratio | 2.63 | ||
| PS Ratio | 125.31 | ||
| EV-to-EBIT | -3.3 | ||
| EV-to-EBITDA | -3.32 | ||
| EV-to-Revenue | 366.3 | ||
| Current Ratio | 7.42 | ||
| Quick Ratio | 7.42 | ||
| Days Sales Outstanding | 378.54 | ||
| Days Payable | 15676.84 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History |
|---|
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.75 | ||
| Price-to-Median-PS-Value | 0.79 | ||
| Price-to-Graham-Number | 0.49 | ||
| Earnings Yield (Greenblatt) % | -30.83 |